This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Song, S. Articles by Au, J. L-S. Search for Related Content PubMed PubMed Citation Articles by Song, S. Articles by Au, J. L-S.

Nontoxic Doses of Suramin Enhance Activity of Paclitaxel against Lung Metastases¹

College of Pharmacy and James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, Ohio 43210

We recently reported that acidic (aFGF) and basic (bFGF) fibroblast growth factors confer a broad spectrum chemoresistance in solid tumors, and that suramin, an inhibitor of multiple growth factors including aFGF and bFGF, enhanced the in vitro antitumor activity of several anticancer drugs including paclitaxel (Song, S., et al., Proc. Natl. Acad. Sci. USA, 97: 8658–8663, 2000). The present study investigated in vitro and in vivo interaction between paclitaxel and suramin, using human PC3-LN cells which, upon i.v. injection into immunodeficient mice, yielded lung metastases in 100% of animals. In in vitro studies, conditioned medium (CM) obtained from histocultures of rat lung metastases induced a 3-fold resistance. The addition of suramin had no effect in the absence of CM but reversed the CM-induced resistance; calculations based on the IC₅₀ values indicate a complete reversal in the presence of <20 µM suramin. Analysis by the combination index method indicates a synergistic interaction between paclitaxel and suramin. In in vivo studies, animals with well-established lung metastases (at least five nodules of 1 mm in diameter) were treated i.v. with paclitaxel (15 mg/kg) and suramin (10 mg/kg) administered twice weekly for 3 weeks. Single-drug therapy with paclitaxel or suramin did not reduce body weight. Suramin alone had no antitumor activity. Paclitaxel alone reduced the tumor size by 75%, reduced the density of nonapoptotic cells by 70% in residual tumors, and enhanced the fraction of apoptotic cells by 3-fold. The addition of suramin to paclitaxel therapy enhanced the antitumor effect, resulting in an additional 5-fold reduction of tumor size, an additional 9-fold reduction of the density of nonapoptotic cells, and an additional 30% increase in the apoptotic cell fraction. These data indicate significant enhancement of the efficacy of paclitaxel by suramin and support the use of nontoxic doses of suramin with paclitaxel in the treatment of lung cancer.

This article has been cited by other articles:

				C. M. Cebulla, M.-E. Jockovich, Y. Pina, H. Boutrid, A. Alegret, A. Kulak, A. S. Hackam, S. K. Bhattacharya, W. J. Feuer, and T. G. Murray Basic Fibroblast Growth Factor Impact on Retinoblastoma Progression and Survival Invest. Ophthalmol. Vis. Sci., December 1, 2008; 49(12): 5215 - 5221. [Abstract] [Full Text] [PDF]

				M. A. Villalona-Calero, G. A. Otterson, M. G. Wientjes, F. Weber, T. Bekaii-Saab, D. Young, A. J. Murgo, R. Jensen, T.-K. Yeh, Y. Wei, et al. Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study Ann. Onc., November 1, 2008; 19(11): 1903 - 1909. [Abstract] [Full Text] [PDF]

				M. R. Horsman and D. W. Siemann Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies Cancer Res., December 15, 2006; 66(24): 11520 - 11539. [Abstract] [Full Text] [PDF]

				L. D. Mayer, T. O. Harasym, P. G. Tardi, N. L. Harasym, C. R. Shew, S. A. Johnstone, E. C. Ramsay, M. B. Bally, and A. S. Janoff Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol. Cancer Ther., July 1, 2006; 5(7): 1854 - 1863. [Abstract] [Full Text] [PDF]

				L. Zhao, M. G. Wientjes, and J. L-S. Au Evaluation of Combination Chemotherapy: Integration of Nonlinear Regression, Curve Shift, Isobologram, and Combination Index Analyses Clin. Cancer Res., December 1, 2004; 10(23): 7994 - 8004. [Abstract] [Full Text] [PDF]

				A. H. Palamakumbura, S. Jeay, Y. Guo, N. Pischon, P. Sommer, G. E. Sonenshein, and P. C. Trackman The Propeptide Domain of Lysyl Oxidase Induces Phenotypic Reversion of Ras-transformed Cells J. Biol. Chem., September 24, 2004; 279(39): 40593 - 40600. [Abstract] [Full Text] [PDF]

				S. Song, B. Yu, Y. Wei, M. G. Wientjes, and J. L.-S. Au Low-Dose Suramin Enhanced Paclitaxel Activity in Chemotherapy-Naive and Paclitaxel-Pretreated Human Breast Xenograft Tumors Clin. Cancer Res., September 15, 2004; 10(18): 6058 - 6065. [Abstract] [Full Text] [PDF]

				A. H. Palamakumbura, P. Sommer, and P. C. Trackman Autocrine Growth Factor Regulation of Lysyl Oxidase Expression in Transformed Fibroblasts J. Biol. Chem., August 15, 2003; 278(33): 30781 - 30787. [Abstract] [Full Text] [PDF]

				M. A. Villalona-Calero, M. G. Wientjes, G. A. Otterson, S. Kanter, D. Young, A. J. Murgo, B. Fischer, C. DeHoff, D. Chen, T.-K. Yeh, et al. Phase I Study of Low-Dose Suramin as a Chemosensitizer in Patients with Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., August 1, 2003; 9(9): 3303 - 3311. [Abstract] [Full Text] [PDF]

				E. J. Small, S. Halabi, M. J. Ratain, G. Rosner, W. Stadler, D. Palchak, E. Marshall, R. Rago, V. Hars, G. Wilding, et al. Randomized Study of Three Different Doses of Suramin Administered With a Fixed Dosing Schedule in Patients With Advanced Prostate Cancer: Results of Intergroup 0159, Cancer and Leukemia Group B 9480 J. Clin. Oncol., August 15, 2002; 20(16): 3369 - 3375. [Abstract] [Full Text] [PDF]